Restless Legs Syndrome

Understanding Restless Legs Syndrome

A Sensorimotor Disorder

RLS sits at the boundary between sensation and movement. Patients describe uncomfortable sensations deep in the legs — crawling, pulling, aching, electric, fizzing, or simply indescribable — that compel them to move. Movement provides immediate but temporary relief. The sensations are not pain in the usual sense, not cramps, not numbness or tingling of neuropathy, and not anxiety, though all of these are common misinterpretations.

Brain Iron and Dopamine

Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Imaging and post-mortem studies show reduced iron in the substantia nigra and other dopamine-rich regions in RLS, even when peripheral iron is normal. This regional iron deficiency leads to a paradoxical state of increased synaptic dopamine but with downregulated receptors and disrupted circadian regulation — explaining why symptoms worsen in the evening when central dopamine signaling normally falls.

The Circadian Pattern

A hallmark of RLS is its circadian rhythm. Symptoms typically begin or intensify in the evening, peak between roughly 11 p.m. and 4 a.m., and recede in the early morning hours. This timing closely mirrors the circadian rhythm of dopamine and corresponds with the time at which patients are usually trying to sleep. The same patient who can sit through a long workday may find it impossible to stay still during an evening movie.

Beyond Just the Legs

Although the legs are the prototypical site, the arms and trunk can also be affected, particularly as RLS progresses. Symptoms are usually bilateral but may be asymmetric. RLS can also affect young children, where it is sometimes mistaken for growing pains or ADHD-related restlessness. Childhood and adolescent RLS is recognized in current criteria and benefits from the same treatment principles applied to adults.

Diagnostic Criteria (URGE)

The diagnosis of RLS is clinical and is based on five essential criteria established by the International Restless Legs Syndrome Study Group (IRLSSG) and incorporated into the ICSD-3. The first four can be remembered with the URGE mnemonic.

1. Urge to Move

An urge to move the legs, usually accompanied by or felt to be caused by uncomfortable and unpleasant sensations in the legs. The urge is the defining feature — patients are compelled to move even when they would prefer to rest.

2. Rest Worsens

The urge to move and the sensations begin or worsen during periods of rest or inactivity, such as lying down or sitting still in a chair, plane, car, or theater. The longer the period of rest, the more intense the urge typically becomes.

3. Getting Up Improves

The urge and sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues. Some patients report that gentler movements such as flexing the feet or rubbing the legs can suffice.

4. Evening Worse

The urge and sensations are worse in the evening or night than during the day, or occur only in the evening or night. In long-standing or severe RLS, this circadian variation may diminish, with symptoms occurring throughout the day.

5. Not Solely Accounted for by Mimicking Conditions

The occurrence of the above features is not solely accounted for as symptoms primary to another medical or behavioral condition (such as leg cramps, positional discomfort, myalgia, venous stasis, leg edema, arthritis, habitual foot tapping, or neuropathy).

Supportive Features

• Family history of RLS in a first-degree relative
• Periodic limb movements of sleep (PLMS) on polysomnography
• A positive response to a trial of dopaminergic therapy (now used more cautiously)

Clinical Course Specifiers

• Chronic-persistent RLS: symptoms when untreated would occur on average at least twice weekly for the past year
• Intermittent RLS: symptoms when untreated would occur on average less than twice weekly for the past year, with at least five lifetime events

Subtypes and Variants

Primary (Idiopathic) RLS

Primary RLS often has a strong family history, with autosomal dominant inheritance evident in some pedigrees. Onset is typically before age 45, sometimes in childhood, with gradual worsening over decades. Genetic studies have identified loci including BTBD9, MEIS1, and MAP2K5, several of which are involved in iron metabolism and embryonic development of sensorimotor circuits.

Secondary RLS

Secondary RLS arises from identifiable conditions and typically improves when those conditions are treated. The most important secondary causes are:

• Iron deficiency, with or without anemia
• End-stage renal disease, particularly in patients on dialysis
• Pregnancy, especially the third trimester
• Peripheral neuropathy
• Spinal cord lesions

Pregnancy-Associated RLS

RLS affects up to 20–25 percent of pregnant women, peaking in the third trimester and usually resolving within weeks of delivery. It is associated with iron and folate status, hormonal changes, and possibly impaired venous return. Women who experience pregnancy-related RLS are at higher risk of developing chronic RLS later in life.

Renal RLS

RLS is dramatically more common in patients with chronic kidney disease, especially those on hemodialysis, where prevalence can exceed 30 percent. Mechanisms include iron deficiency, uremia, and altered dopaminergic signaling. Renal RLS frequently improves after kidney transplantation.

Medication-Induced RLS

Many commonly prescribed medications can precipitate or worsen RLS:

• Most antidepressants, particularly SSRIs, SNRIs, and mirtazapine (bupropion is the notable exception)
• First- and second-generation antipsychotics through dopamine receptor blockade
• Sedating antihistamines (diphenhydramine, hydroxyzine)
• Centrally acting antiemetics such as metoclopramide and prochlorperazine
• Some lithium and beta-blocker regimens

Symptoms and Patterns

The Sensory Component

Patients describe RLS sensations in highly variable terms — crawling, creeping, tingling, electric, fizzy, achy, itchy deep inside, like soda bubbles in the bones — but most agree that the experience is qualitatively unlike any other discomfort. The sensations are typically deep within the limb rather than on the skin, and they are bilateral, although they may shift sides night to night.

The Motor Component

The urge to move is what differentiates RLS from other sensory complaints. Patients pace, stretch, flex their feet, rub their calves, take hot baths, get out of bed multiple times, and try a long list of behavioral remedies. Many find themselves walking the house at 2 a.m., unable to lie down again until the symptom subsides.

Periodic Limb Movements of Sleep (PLMS)

Up to 80 percent of RLS patients have PLMS — stereotyped, repetitive flexion movements of the legs during sleep, typically every 20 to 40 seconds, often clustered in non-REM stages. PLMS may fragment sleep without the patient's awareness; bed partners often describe the kicking. When PLMS occurs without RLS symptoms but produces clinical impairment, the condition is called periodic limb movement disorder.

Daytime Consequences

• Daytime fatigue and sleepiness
• Difficulty concentrating
• Low mood and irritability
• Reduced productivity
• Anxiety about evenings, travel, theater, or any anticipated stillness

Severity

The International Restless Legs Syndrome Rating Scale (IRLS) is a widely used 10-item self-report measure that grades severity from mild to very severe. It is useful both for initial assessment and for tracking response to treatment.

Causes and Risk Factors

Iron Deficiency: The Central Lever

Iron deficiency, particularly in the brain, is at the core of RLS pathophysiology. Patients can have RLS with normal hemoglobin and even with serum iron in the normal range; what matters most is brain iron, which is imperfectly reflected by ferritin and transferrin saturation. Current consensus recommends maintaining serum ferritin above approximately 75 ng/mL and transferrin saturation above 20 percent in patients with RLS. Ferritin in the lower portion of the conventional normal range is often functionally inadequate for symptom control.

Dopaminergic Dysfunction

The link between iron and dopamine explains why dopaminergic drugs are effective in RLS. But the picture is more complex than a simple dopamine deficit. Patients actually appear to have increased dopamine in the brain with downregulated receptors, fitting a model of receptor desensitization. Over time and with long-term dopamine agonist exposure, this dysregulated system contributes to augmentation, the worsening of symptoms despite treatment.

Genetics

Family history is present in roughly half of patients with primary RLS. Several risk loci have been identified, with MEIS1 and BTBD9 among the most replicated. These loci are also linked to PLMS, suggesting overlap between the two phenotypes.

Pregnancy and Sex Hormones

The female predominance of RLS, the spike of incidence during pregnancy, and the role of estrogen modulation suggest sex-hormonal influences, though the precise mechanisms remain incompletely understood.

Renal Disease

Chronic kidney disease, particularly in hemodialysis, dramatically increases RLS risk through iron deficiency, uremia-related dopaminergic disturbance, and other factors. Kidney transplantation usually resolves the symptoms.

Peripheral Neuropathy and Other Neurologic Conditions

Diabetic and other peripheral neuropathies are associated with RLS, and the differential between the two can be difficult. RLS also coexists more often than chance would predict with Parkinson's disease, multiple sclerosis, spinal cord injury, and certain hereditary ataxias.

Lifestyle and Environmental Contributors

• Caffeine, alcohol, and nicotine can worsen symptoms in many patients
• Sleep deprivation amplifies RLS in a vicious cycle
• Sedentary periods (long flights, road trips) trigger symptoms
• Heavy meals close to bedtime can intensify nighttime symptoms in some patients

Medical and Psychiatric Complications

Sleep Disruption

The most direct consequence of RLS is sleep loss. Sleep-onset insomnia is common because patients cannot lie still long enough to fall asleep. Sleep-maintenance insomnia results from PLMS-related arousals and from re-emergence of symptoms during the night. Chronic sleep loss in turn raises risk for cardiovascular disease, metabolic dysfunction, and mood disorders.

Mood and Anxiety

RLS is associated with two- to fourfold increased rates of depression and anxiety. Part of this reflects the burden of chronic sleep loss and chronic discomfort; part may reflect shared neurobiology in dopaminergic and limbic systems. Treatment is complicated by the fact that many antidepressants can worsen RLS.

Cardiovascular Risk

Long-term RLS, especially with severe PLMS, has been associated with hypertension and possibly cardiovascular events. The mechanism likely involves repeated sympathetic surges with each periodic movement and chronic sleep loss.

Cognitive Impact

Patients often describe daytime cognitive fog — difficulty with attention, working memory, and processing speed. These deficits are largely attributable to sleep loss rather than primary cognitive impairment.

Augmentation

Augmentation is the most important iatrogenic complication of RLS treatment. After months to years of dopamine agonist therapy, symptoms paradoxically worsen — beginning earlier in the day, spreading to other limbs, becoming more intense, and reappearing soon after each dose. Augmentation has reshaped clinical practice and is a major reason why alpha-2-delta ligands are increasingly first-line.

Assessment and Diagnosis

Clinical Interview

RLS is a clinical diagnosis based on the URGE criteria. A careful history can confirm the diagnosis in most patients without specialized testing. The clinician should ask about timing of symptoms (rest, evening), responses to movement, family history, sleep effects, medication exposures, and the presence of mimicking conditions.

Differential Diagnosis

• Peripheral neuropathy (sensations more constant, on the skin, not relieved by movement)
• Nocturnal leg cramps (sudden painful contractions, not preceded by an urge)
• Akathisia (often medication-induced, generalized restlessness, less circadian)
• Vascular claudication (worse with exertion, relieved by rest)
• Positional discomfort and venous insufficiency
• Painful legs and moving toes syndrome
• Anxiety with motor restlessness

Laboratory Evaluation

Every patient with RLS should have iron studies. The minimum panel includes:

• Serum ferritin (target greater than 75 ng/mL for symptom control)
• Transferrin saturation (target greater than 20 percent)
• Complete blood count
• Renal function
• Fasting glucose or HbA1c when neuropathy is suspected
• Thyroid function in selected patients

Polysomnography

Routine polysomnography is not required for RLS diagnosis. It is used when symptoms are atypical, when significant sleep apnea is suspected, when PLMS is the dominant feature, or when treatment is failing without clear cause. PLMS index can be quantified.

Other Investigations

Nerve conduction studies and electromyography are reserved for patients with clinical features suggesting peripheral neuropathy. Imaging is not routinely indicated.

Treatment Approaches

Step 1: Address Iron and Reversible Factors

The first step in nearly every patient with RLS is to optimize iron status. Oral iron (such as ferrous sulfate or ferrous bisglycinate, often dosed every other day for better absorption) raises ferritin in most patients with mild deficits. Vitamin C taken with iron improves absorption. In patients with severe symptoms, poor oral tolerance, or persistent low ferritin, intravenous iron formulations such as ferric carboxymaltose or low-molecular-weight iron dextran can produce rapid and substantial symptom improvement. Reviewing and adjusting offending medications — many antidepressants, antipsychotics, antihistamines, and antiemetics — is the other essential early step.

Step 2: Non-Pharmacological Strategies

• Regular moderate exercise — improves symptoms in most patients
• Reducing or eliminating caffeine, alcohol, and tobacco
• Stretching, leg massage, and warm or cool baths in the evening
• Pneumatic compression devices, which have modest evidence in mild RLS
• Consistent sleep schedule and good sleep hygiene
• Mental engagement during periods of rest (puzzles, conversation, knitting) to reduce symptom emergence

Alpha-2-Delta Ligands

Gabapentin enacarbil (a prodrug of gabapentin), pregabalin, and gabapentin itself bind the alpha-2-delta subunit of voltage-gated calcium channels and reduce RLS symptoms without producing augmentation. They are increasingly recommended as first-line pharmacotherapy by current professional guidelines, particularly for patients with painful RLS, comorbid pain or anxiety, and chronic-persistent disease. Side effects include sedation, dizziness, peripheral edema, and weight gain; gabapentin enacarbil has the most consistent absorption profile among the three.

Dopamine Agonists

Pramipexole, ropinirole, and the rotigotine transdermal patch were long considered first-line for moderate to severe RLS. They are highly effective in the short term, with rapid symptom relief at low doses. However, long-term use carries two important risks:

• Augmentation: the worsening of symptoms over time despite treatment, with earlier onset, spread to other limbs, and increased intensity. Augmentation affects a meaningful proportion of patients on long-term dopamine agonists and is the main reason these drugs are no longer always first-line
• Impulse control disorders: compulsive gambling, shopping, eating, and hypersexual behavior, mediated by D3 receptor stimulation

When dopamine agonists are used, the lowest effective dose, vigilance for augmentation, and screening for impulse control disorders are essential.

Opioids

Low-dose opioids — such as oxycodone, methadone, or tramadol — are highly effective in severe and refractory RLS, including in patients with augmentation from prior dopamine agonist therapy. Although their use raises understandable concerns, addiction in carefully selected RLS patients on stable low doses has been relatively uncommon in observational studies. Opioids are reserved for cases where iron repletion, alpha-2-delta ligands, and behavioral measures have failed.

Benzodiazepines

Clonazepam and other benzodiazepines may improve sleep quality but do not directly treat RLS sensations. They are not first-line but can be useful adjuncts in selected patients.

Managing Augmentation

When augmentation occurs, the approach is to first ensure iron is replete, then either switch from a short-acting to a longer-acting dopaminergic agent (such as rotigotine patch), substitute an alpha-2-delta ligand, or cross-taper to an opioid in severe cases. Simply increasing the dopamine agonist dose typically worsens augmentation and should be avoided.

Pregnancy and RLS

Pharmacological options in pregnancy are limited. The mainstays are iron supplementation, gentle behavioral measures, and avoidance of aggravating medications. Most agents are avoided or used cautiously after specialist consultation, and most pregnancy-related RLS resolves spontaneously after delivery.

Living With RLS

Plan for Rest

Long flights, theater visits, road trips, and meetings that involve prolonged stillness can be planned around. Strategies include scheduling these activities earlier in the day when symptoms are milder, choosing aisle seats, taking breaks to walk, and timing medication appropriately.

Engage the Mind

Mental engagement reduces RLS symptoms in many patients. Knitting, puzzles, video games, animated conversation, or reading that demands attention can substantially blunt the emergence of symptoms during periods of forced rest.

Track Triggers

Keeping a simple log of symptoms alongside diet, exercise, medications, and sleep can identify personal triggers that are not obvious. Common but variable triggers include alcohol, late caffeine, certain SSRIs, and disrupted sleep schedules.

Communicate With Bed Partners

RLS and PLMS can disrupt a partner's sleep as much as the patient's. Honest conversation about kicking, getting in and out of bed, and the need for separate sheets, larger beds, or occasionally separate sleeping rooms is often valuable.

Mental Health Care

Because depression and anxiety are common in RLS, and because some standard antidepressants can worsen symptoms, mental health care for RLS patients benefits from coordination. Bupropion and selected serotonergic agents with less RLS impact may be considered, along with non-pharmacological treatments such as cognitive behavioral therapy.

Supporting a Loved One

Take the Symptoms Seriously

RLS is sometimes dismissed as fidgeting or anxiety. Recognizing that the sensations are real, often distressing, and treatable is the foundation of support. The patient is not being dramatic — they are dealing with a genuine sensorimotor disorder.

Encourage Iron Testing

Many patients are never told that iron status drives their symptoms. Encouraging a loved one to ask their clinician for ferritin and transferrin saturation testing, and to treat low values, can be one of the most useful interventions a family member can prompt.

Be Patient With Sleep Disruption

Bed partners may share the consequences of fragmented sleep. Patience, flexibility around sleeping arrangements, and respect for the patient's need to get up and move all support better outcomes.

Watch for Augmentation and Impulse Control Issues

For patients on dopamine agonists, family members are often the first to notice augmentation (symptoms creeping earlier into the day) or new gambling, shopping, or eating behaviors. Reporting these promptly to the prescribing clinician can prevent serious harm.

Support a Healthy Lifestyle

Encouraging regular exercise, balanced meals with adequate iron-containing foods, moderating caffeine and alcohol, and protecting sleep all help the patient stay in the best position to manage symptoms.